AUSTIN, Texas, July 21, 2021 /PRNewswire/ -- Natera, Inc.
(Nasdaq: NTRA), a pioneer and global leader in cell-free DNA
testing, today announced the pricing of its underwritten public
offering of 4,500,000 shares of its common stock at a price to the
public of $113.00 per share. Closing
of the offering is expected to occur on July
26, 2021, subject to customary closing conditions. In
addition, Natera has granted the underwriters a 30-day option to
purchase up to an additional 675,000 shares of its common stock at
the public offering price less the underwriting discounts and
commissions.
Morgan Stanley, Goldman Sachs & Co. LLC, Cowen and SVB
Leerink are acting as joint book-running managers for the offering.
Baird, BTIG and Craig-Hallum are
acting as co-managers for the offering.
The securities described above are being offered pursuant to an
automatically effective shelf registration statement on Form S-3
that was filed with the U.S. Securities and Exchange Commission on
July 20, 2021. The offering is being made only by means
of an effective registration statement, including a preliminary
prospectus and, when available, final prospectus, copies of which
may be obtained by contacting Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor,
New York, NY 10014; Goldman Sachs
& Co. LLC, Attn: Prospectus Department, 200 West Street,
New York, New York 10282, or by
telephone at (866)471-2526 or by emailing
prospectus-ny@ny.email.gs.com; Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY, 11717, Attn:
Prospectus Department, by email at
PostSaleManualRequests@broadridge.com or by telephone at (833)
297-2926; or SVB Leerink LLC, Attention: Syndicate Department, One
Federal Street, 37th Floor, Boston,
MA 02110, by telephone at 1-800-808-7525 ex. 6105 or by
email at syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Natera
Natera is a pioneer and global leader in cell-free DNA testing from
a simple blood draw. The mission of the company is to change the
management of disease worldwide with a focus on women's health,
oncology, and organ health. Natera operates ISO 13485-certified and
CAP-accredited laboratories certified under the Clinical Laboratory
Improvement Amendments (CLIA) in Austin,
Texas and San Carlos,
California. It offers proprietary genetic testing services
to inform obstetricians, transplant physicians, oncologists, and
cancer researchers, including biopharmaceutical companies, and
genetic laboratories through its cloud-based software platform.
Forward-looking Statements
Except for historical information, certain statements in this press
release, including statements regarding the closing of the
follow-on offering are forward-looking in nature and are subject to
risks, uncertainties and assumptions about Natera and its business,
including, without limitation, risks and uncertainties related to
satisfaction of the closing conditions related to the follow-on
offering. Such forward-looking statements involve substantial risks
and uncertainties that relate to future events and the actual
results could differ significantly from those expressed or implied
by the forward-looking statements. Any forward-looking statements
are based on Natera's current expectations, estimates and
assumptions regarding future events and are applicable only as of
the dates of such statements. Natera makes no commitment
to revise or update any forward-looking statements in order to
reflect events or circumstances that may change, except as required
by law. For a further description of the risks and uncertainties
that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating
to Natera's business in general, please refer to the "Risk
Factors" section in Natera's automatically effective
shelf registration statement on Form S-3 filed with the Securities
and Exchange Commission (the "SEC") on July
20, 2021, including the documents incorporated by reference
therein, including its Annual Report on Form 10-K filed
with the SEC on February 26, 2021 and its Quarterly
Report on Form 10-Q filed with the SEC on May 7, 2021.
Natera Contacts
Investor Relations: Mike Brophy,
CFO, Natera, Inc., 650-249-9090
Media: Kate Stabrawa,
Communications, Natera, Inc., 720-318-4080
pr@natera.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/natera-announces-pricing-of-follow-on-offering-301339136.html
SOURCE Natera, Inc.